ABSTRACT-Both analgesic and ulcerogenic activities of d-2-[4-(3-methyl-2-thienyl)phenyl] propionic acid (M-5011), a novel non-steroidal anti-inflammatory drug (NSAID), were compared with those of indomethacin (IND), ketoprofen (KP), diclofenac sodium (DIF), zaltoprofen (ZLT) and tiaprofenic acid (TIA) in mice. All orally administered NSAIDs including M-5011 inhibited kaolin-induced writhing in a dosedependent manner. M-5011 had an effective antinociceptive activity (ED50 value) of 0.63 mg/kg, being more potent than ZLT (16.80 mg/kg) and TIA (4.78 mg/kg), equipotent to DIF (0.68 mg/kg), and less potent than IND (0.21 mg/kg) and KP (0.28 mg/kg). All drugs tested significantly reduced peritoneal 6-ketoprostaglandin Fla (6-keto-PGFIa) levels at the peak kaolin-induced writhing time (7.5 min post-kaolin injection) without affecting peritoneal bradykinin (BK) levels. Antinociceptive effects of all drugs were closely correlated with inhibition of peritoneal 6-keto-PGFIa levels. 
Acidic nonsteroidal anti-inflammatory drugs (NSAIDs) such as aspirin, indomethacin (IND), ketoprofen (KP) and diclofenac sodium (DIF), which show potent antiinflammatory effects, are extensively used for the therapy of severe inflammatory diseases such as rheumathrosis (1) . The underlying mechanism of anti-inflammatory effects of acidic NSAIDs is mainly attributed to inhibition of the excessive production of prostaglandins (PG) at inflammatory sites (2, 3). Recently, we have innovated a novel acidic NSAID, d-2-[4-(3-methyl-2-thienyl)phenyl]
propionic acid (M-5011). In the preliminary study, M-5011 elicited potent anti-inflammatory effects in ultraviolet-induced erythema and carrageenin-induced edema tests, and these effects are at least equipotent to those of IND.
Apart from the anti-inflammatory effects, acidic NSAIDs possess analgesic activities (4, 5) . However, the use of acidic NSAIDs for the relief of pain accompanied by inflammation is limited by their undesirable gastrointestinal ulcerogenesis, which is derived from inhibition of PGs biosynthesis (6) . To date, incessant efforts have been directed towards the development of potent NSAIDs devoid of ulcerogenicity. Kaolin-induced writhing, mainly mediated by both endogenous bradykinin (BK) and PGI2, is one of the reliable and simple tests for the evaluation of analgesic agents (7) . The present study was undertaken to clarify both the analgesic effects on this chemonociceptive response and gastrointestinal ulcerogenicity of M-5011 in mice compared with those of other acidic NSAIDs.
Animals
Both male ICR (3 weeks; Shizuoka Laboratory Center, Hamamatsu) and ddY mice (4 weeks, Shizuoka Laboratory Center) housed in individual cages with free access to food and water were kept in a room maintained at constant temperature (23±2C) and relative humidity (55:±1007o) with an alternating 12-hr light/dark cycle (lighting on at 07:00 a.m.) 
Drugs
The chemical structure of M-5011 (Maruho Co., Ltd., Osaka) is shown in Fig. 1 . Indomethacin (IND), ketoprofen (KP) and diclofenac sodium (DIF) (Sigma Chem. Co., St. Louis, MO, USA) were used as reference drugs. Zaltoprofen (ZLT) and tiaprofenic acid (TIA) were respectively extracted from Soleton® (Nippon Chemiphar Co., Ltd., Tokyo) and Surgam® (Nippon Roussel, Tokyo) at our laboratories. Briefly, a mixture of each drug with ethyl acetate was refluxed and then filtered. The filtrate was evaporated to dryness with a rotating evaporator. The residue was recrystallized from toluene. The purities of ZLT and TIA determined by high-performance liquid chromatography were 99.7% and 99.9%, respectively.
Preparation of test drugs
All drugs for dosing were freshly prepared at 7-day intervals. These drugs were suspended in 0.5% carboxymethylcellulose sodium (CMC) (Wako Pure Chemical Co., Osaka) at the highest concentration possible. Lower concentrations were then prepared by serial dilution whenever and wherever applicable.
Kaolin-induced writhing response
The chemonociceptive response was performed as previously described with a slight modification (8) . Male ICR mice (4 weeks) were fasted overnight (fasted weight under 22 g) with free access to water before the experiments. Groups of 10-14 mice each were administered with M-5011 (3.00, 1.00, 0.30, 0.10 or 0.03 mg/kg), IND Assay of bradykinin and 6-keto-PGFIa Mice were sacrificed by exsanguination at various times after kaolin injection, and the peritoneal cavity was surgically exposed to collect the exudate. To inhibit the breakdown and production of kinins during exudate collection (9), 2 ml of saline-ethanol (80 : 1) containing 62.5 pg of soybean trypsin inhibitor (Sigma Chem. Co.), 62.5 pg of aprotinin (Sigma Chem. Co.), 17.5 pg of polybrene (Sigma Chem. Co.), 75.0 pg of disodium ethylenediamine tetraacetate (Dojin Chemical Co., Kumamoto) and 42.5 pg ortho-fenanthroline (Nacalai Tesque, Kyoto) were injected into the peritoneal cavity immediately after exsanguination. The peritoneal fluids collected with a polyethylene pipet was placed in a polypropylene tube before adding ethanol (final concentration: 80%). After standing for 1 hr at 0'C, the mixture was centrifuged at 1,500 x g for 15 min at 4C. The isolated supernatant was evaporated to dryness at 37 C with a rotating evaporator. Desiccated samples were kept at -801C until assay. Desiccated samples dissolved in 500 p1 of distilled water were treated with 1/5 vol. of 20% trichloroacetic acid (TCA) to remove protein prior to centrifugation at 1,500 x g for 10 min at 4C. The supernatants were collected and diluted at 1 : 1 with an appropriate buffer (buffer B of the MARKIT-M-Bradykinin®; Dainippon Pharmaceutical, Osaka) for enzyme immunoassay with an assay kit (MARKIT-M-Bradykinin®), which is based on a competitive reaction between the enzyme-labeled bradykinin (BK) and kinins in the BK antibody. The kinin concentrations of samples were expressed in terms of the standard BK concentration. The lower and upper detection limits of BK were within 0.1-100 ng/ml, and the recovery rate of BK throughout the collection of peritoneal washing was 60.5-L0.63% (mean ± S. E. , n=3). Inhibition (%) was calculated as follows:
where A=BK levels in the control group of each test and B = BK levels in the drug-treated group.
The 6-keto-PGFIa contents were determined by exudates of another kaolin-injected group. Saline solution (2 ml) containing 1.4 x 10-4 M indomethacin (Sigma Chem. Co.) was injected i.p. immediately after exsanguination to inhibit formation of PGs in the peritoneal cavity during exudate collection. At designated intervals after the initiation of kaolin-induced writhing, exudates were completely collected in polypropylene tubes. The samples were centrifuged at 1,500 x g for 10 min at 41C before the supernatants were frozen immediately under a stream of nitrogen gas and stored at -80V until assay. Extraction of 6-keto-PGFIa was performed by the Powell method (10) with a slight modification. The samples were acidified to pH 3.0 with 1 N HCl and loaded onto a SEP-PAK C18 cartridge (Waters Associates, Milford, MA, USA) previously washed with 5 ml each of methanol and distilled water. The cartridges were then washed serially with 5 ml each of distilled water, ethanol and benzene, before 6-keto-PGFIa was finally eluted with 5 ml of ethyl acetatemethanol (9 : 1). The eluant were evaporated to dryness at room temperature with a rotating evaporator. Desiccated samples dissolved in 1.5 ml of distilled water were diluted with buffer (6-keto-PGFIa EIA system; Amersham Int. plc., Buckinghamshire, England), and 6-ketoPGFIa contents were determined by the enzyme immunoassay method (6-keto-PGFIa EIA system) based on a competitive reaction of enzyme-labeled 6-keto-PGFIa in the samples for 6-keto-PGFIa antibodies. The lower and upper detection limits of 6-keto-PGFIa were within 10-1,280 pg/ml. Inhibition (%) was calculated as follows:
where A=6-keto-PGFIa level in the control group and B=6-keto-PGFIa level in the drug-treated group.
Ulcerogenic test
According to the report by Imayoshi et al. (11) , with a slight modification, groups of 10 ddY mice (5 weeks Mice were then injected i.v. with 0.2 ml of saline solution containing 1% Evan's blue (Sigma Chem. Co.) before sacrifice by exsanguination. Stomachs and whole small intestines (from pyloric end to ileocecal part) were isolated, fixed by intraluminal irrigation with 2 ml of 1 % formalin solution (Nacalai Tesque) prior to ulceration analysis under microscopy. The incidence of ulceration, including ecchymosis, was evaluated on an all-or-none basis.
Statistical analyses
Results are expressed as the mean±S.E. Statistical significance between the differences of means was verified by the multiple comparison test (Williams method). ED50 values for kaolin-induced writhing (doses required to inhibit 50% of the response) and ID50 values (doses required to inhibit 50% of 6-keto-PGFIa by kaolin production) were calculated by linear regression analysis using inhibition percentages. UD50 values and 95% confidence limits (CL) of ulcerogenicity were determined by probit analysis using the ulceration incidence. 
Effects of NSAIDs on kaolin-induced writhing
Total writhing responses for 15 min after kaolin injection in the control group were more than 12 (14.34±0.87, in 4 tests). Writhing responses attained a peak at 10 min after kaolin injection and then attenuated at 15 min (Fig.  2) . M-5011 inhibited kaolin-induced writhing responses in a dose-dependent manner ( Table 1 ). The ED50 value of M-5011 (0.63 (0.26-1.54, 95% CL) mg/kg) against writhing was 7.6-to 26.7-fold lower than that of TIA Table 1) .
Effects of NSAIDs on BK levels induced by kaolin injection
Kaolin-induced BK production in the peritoneal cavity from 3 to 10 min post-injection (Fig. 3) . Peritoneal BK levels in the control group peaked at 5 min post-injection of kaolin (7.60± 1.83 ng/mouse) and decayed gradually thereafter. Similar treatment with physiological saline (0.5 ml) did not induce any BK production, indicating that peritoneal BK was released by kaolin. Pretreatment (1 hr before kaolin injection) with all drugs (M-5011, IND, KP and DIF: 3.0 mg/kg; TIA: 10.0 mg/kg; or ZLT 30 mg/kg) did not affect peritoneal BK production at 5 min post-injection of kaolin with the indicated doses (data not shown).
Test compounds were administered orally 1 hr before i.p. injection of kaolin suspension (2.5 mg in 0.5 ml of saline) containing 0.05 mg of captopril. Each group consisted of 10-14 mice. The ED50 values and 95% confidence limits (CL) were calculated by regression analysis using inhibition percentage. Potency ratios of drugs were calculated with indomethacin =1. Significant difference from the control, *P<0.05, **P<0.01.
Effects of NSAIDs on kaolin-induced 6-keto-PGFIa production Kaolin-induced 6-keto-PGFIa production in the peritoneal cavity from 5 to 15 min post-injection (Fig. 3) . Peritoneal 6-keto-PGFIa contents in the control group peaked at 10 min (16.54±3.04 ng/mouse) and decayed thereafter. Similar treatment with physiological saline (0.5 ml) did not induce any 6-keto-PGFIa production (less than 0.12 ng/mouse), implicating that peritoneal 6-ketoPGFIa was dependent on kaolin injection. Pretreatments with M-5011 and other NSAIDs (1 hr before kaolin injection) elicited dose-related decreases in peritoneal 6-ketoPGFIa contents at 7.5 min post-injection of kaolin, coinciding well with the peak number of kaolin-induced writhing responses. 
Effects of NSAIDs on gastric mucosa in mice
The vehicle (CMC) did not produce any stomach ulcers. All drugs (including M-501 1) produced dose-dependent ulceration (Fig. 4A) . The UD50 value of M-5011 (Table 3) . Furthermore, M-5011 was respectively 4.4-, 9.8-and 21.1-fold less potent than KP (20.04 (15.87-25.98) mg/kg), IND (8.96 (7.12-11.57) mg/kg) and DIF (4.19 (3.28 -5.52) mg/kg) in gastric ulcerogenicity.
Effects of NSAIDs on small intestinal mucosa in mice
In a similar tendency, all drugs induced small intestinal ulceration in a dose-dependent manner (Fig. 4B) It is well-known that substances with a negative surface charge such as kaolin activate the kallikrein-kinin system through activation of blood coagulation factor XII (12) . In consequence, activation of the plasma kallikrein-kinin system induces the generation of BK, causing potent pain (13). Fujiyoshi et al. (8, 9) reported that the intraperitoneal injection of kaolin produced kinin in the peritoneal cavity of the mouse resulting in the writhing reaction. Thus, it seems that kaolin-induced writhing is mainly based on BK. In addition to the effect of BK, it is suggested that the sensory nerve-sensitizing effect of PGI2i an arachidonic acid metabolite, may play an important role in the pain reaction in kaolin-induced writhing, from the evidence that this writhing reaction was markedly decreased by administration of acidic NSAIDs such as IND that inhibit of cyclo-oxygenase (14) . Furthermore, Joseph and Barry (15) and Hori et al. (16) reported that PGI2 was the most powerful substance to cause a sensitizing potency of BK and acetic acid among the other arachidonic metabolites. Taken together, it seems reasonable to consider that both BK and PGI2 is closely related to kaolin-induced writhing. Therefore, in the present study, we tried to clarify the effects of M-5011 and other NSAIDs on the production of PGI2 or BK in kaolin-induced writhing.
In the present study, an intraperitoneal injection of kaolin in mice caused clear and reproducible writhing reactions attaining a peak at 5 -10 min after kaolin injection in agreement with the report of Fujiyoshi et al. (8) . M-5011 and other NSAIDs elicited dose-dependent suppressive effects on kaolin-induced writhing. Based on ED50 values derived from these results, the potency rank order of the drugs was as follows: IND ? KP > M-5011 >_ DIF > TIA > ZLT . Furthermore, at the peak of the writhing responses, these drugs significantly reduced the peritoneal contents of 6-keto-PGFIa, a stable metabolite of PGI2i in a dose-dependent manner, but not the production of BK in agreement with previous findings (12, 14) . Thus, the potency rank of ID50 values of these drugs on PGI2 production was similar to that of the antinociceptive potency ranking of ED50 values. As a result, the present study indicates that the differences in the antinociceptive potency of these acidic NSAIDs with kaolin-induced writhing are at least partly based on the potency of inhibition of PGI2 generation as stated in the above findings (12, 14) .
Apart from the antinociceptive potency of these acidic NSAIDs accompanied by inhibition of PGI2 generation, M-5011 displayed lower ulcerogenicity than IND, KP and DIF, and only TIA and ZLT, which had weak antinociceptive effects, showed lower ulcerogenicity. As a result, M-5011 revealed the highest analgesic safety index (UD50/ED50). Although the mechanisms underlying the ability of NSAIDs to damage the gastrointestinal mucosa are not completely understood, there are a few reports suggesting that unwanted gastric lesions induced by acidic NSAIDs are due to cyclooxygenase (COX) inhibition, which in turn decreases PGs production (17). Allison et al. (18) reported that current NSAID therapy against inflammation is often limited by mechanismbased toxicities of these drugs, especially gastrointestinal lesions that are induced by inhibition of PG formation in the stomach and intestine. For the gastric mucosa, PG12i which is a major COX product, elicits protective effects against either gastric or duodenal ulceration, like other PGs (19) . In addition, Kobayashi et al. (20) reported that the differences in ulcerogenicity among IND, TIA and DIF were closely related to their potencies in suppressing PGI2 production in the gastric cavity of rats. Recently, two forms of the COX have been identified: COX-1, which is constitutively expressed in many tissues including the gastrointestinal tract (21) , and COX-2, which is associated with pro-inflammatory PGs production in several tissues and cell types. PGs production induced by COX-1 is involved in physiological functions such as vascular homeostasis, renal function and gastric cytoprotection (22) . Thus, ulcerogenicity associated with NSAIDs may be due to inhibition of COX-1 rather than COX-2. However, we have confirmed that IC50 values of M-5011, IND and ZLT on COX-1 are 7.67, 35.6 and 207.0 1M, respectively (Y. Mukoyama et al., unpublished data). Based on these IC50 values, the rank order of inhibitory action on COX-1 is as follows: M-5011 > IND>ZLT. Thus, the low ulcerogenicity of ZLT can be explained by its low inhibitory activity of COX-1. However, these results contradict the data showing that M-5011 displays lower ulcerogenicity than IND. Therefore, other factors may be involved in the relatively low ulcerogenicity of M-5011. As yet we have no definite explanations about this, but it is plausible that the pharmacokinetic profile of M-5011 may be, at least partly, involved in its ulcerogenicity, indicating that oral M-5011 is rapidly absorbed and more rapidly disappeared from the plasma than IND in mice. Further studies will be required to clarify the low ulcerogenicity of M-501 1.
In conclusion, M-5011 elicited a potent antinociceptive activity of kaolin-induced writhing in mice with low ulcerogenic effects. As shown in the analgesic safety index, the wide separation between the analgesic and gastrointestinal ulcerogenic activities of M-5011 suggests that M-5011 possesses high potential for use in clinical pain, different from the other clinically available NSAIDs at present. 
